Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBITDA (2016 - 2025)

Altimmune (ALT) has disclosed EBITDA for 16 consecutive years, with -$27.3 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 17.0% to -$27.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$88.0 million through Dec 2025, up 7.35% year-over-year, with the annual reading at -$88.0 million for FY2025, 7.35% up from the prior year.
  • EBITDA for Q4 2025 was -$27.3 million at Altimmune, down from -$19.0 million in the prior quarter.
  • The five-year high for EBITDA was -$14.9 million in Q1 2021, with the low at -$33.5 million in Q3 2021.
  • Average EBITDA over 5 years is -$22.7 million, with a median of -$22.3 million recorded in 2024.
  • The sharpest move saw EBITDA crashed 279.24% in 2021, then increased 29.4% in 2022.
  • Over 5 years, EBITDA stood at -$23.9 million in 2021, then rose by 9.65% to -$21.6 million in 2022, then tumbled by 46.04% to -$31.5 million in 2023, then grew by 26.06% to -$23.3 million in 2024, then decreased by 17.0% to -$27.3 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$27.3 million, -$19.0 million, and -$22.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.